Quick Takeaways
- VANGUARD GROUP INC filed SCHEDULE 13G/A for Crinetics Pharmaceuticals Inc Common Stock (CRNX).
- Disclosed ownership: 10%.
- Date of event: 31 Mar 2025.
VANGUARD GROUP INC - 31 Mar 2025 SCHEDULE 13G/A Report for Crinetics Pharmaceuticals Inc Common Stock (CRNX)
- Filing Manager
- VANGUARD GROUP INC
- Reporting Manager
- The Vanguard Group
- Symbol
- CRNX
- Shares outstanding
- 93,116,000 shares
- Disclosed Ownership
- 9,311,600 shares
- Ownership
- 10%
- Form type
- SCHEDULE 13G/A
- Filing time
- 07 Apr 2025, 11:52:11 UTC
- Date of event
- 31 Mar 2025
- Previous filing
- 30 Jan 2025
- Next filing
- 26 Mar 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"VANGUARD GROUP INC disclosed 10% ownership in Crinetics Pharmaceuticals Inc Common Stock (CRNX) on 31 Mar 2025."
What Changed
- Previous schedule filing date: 30 Jan 2025.
- Current filing was accepted on 07 Apr 2025, 11:52.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| The Vanguard Group | 10% | 9,311,600 | 0 | 107,465 | Ashley Grim | Head of Global Fund Administration |